Related Experiment Video
Updated: May 29, 2025

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
Published on: April 5, 2024
Biophysical and structural insights into AAV genome ejection.
Keely Gliwa1, Joshua Hull1, Austin Kansol1
1Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA.
Recombinant adeno-associated virus (rAAV) genome ejection occurs at temperatures higher than capsid disassembly, with low pH and VP1/VP2 absence accelerating this process for improved gene therapy vector efficiency.
Area of Science:
- Molecular biology
- Virology
- Biophysics
Background:
- Recombinant adeno-associated virus (rAAV) is a key gene therapy vector, but its efficiency depends on nuclear delivery.
- Understanding capsid biophysics during intracellular trafficking is crucial for optimizing rAAV efficacy.
- Low pH encountered during endo-lysosomal trafficking triggers viral protein externalization, aiding endosomal escape.
Purpose of the Study:
- To characterize the genome ejection (GE) process for AAV2 and AAV5 serotypes.
- To investigate the influence of temperature, pH, and capsid proteins on GE.
- To elucidate the structural dynamics of capsid-mediated genome release.
Main Methods:
- Temperature-dependent genome ejection assays.
- Quantitative PCR (qPCR) for transgene quantification.
- Transmission electron microscopy (TEM).
- Cryo-electron microscopy (cryo-EM) for structural analysis.
Main Results:
- The temperature for genome ejection (TE) is significantly lower than the capsid disassembly temperature (TM) for AAV2 and AAV5.
- Absence of VP1/VP2 proteins and decreased pH accelerate genome ejection.
- Cryo-EM revealed capsid structural changes consistent with concerted genome egress.
Conclusions:
- Genome ejection is a distinct process from capsid disassembly in rAAV.
- Environmental factors like pH and viral protein composition modulate genome release kinetics.
- Findings suggest a conserved genome ejection mechanism across rAAV serotypes, potentially improving gene therapy vector design.
More Related Videos
21:55Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
Published on: April 2, 2012
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
Published on: October 18, 2022